At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 136 enrolled
Drug / intervention
Tralokinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Tralokinumab for Atopic Dermatitis. Completed, enrolled 136 participants across 29 sites.
Detailed Summary
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedJan 2022
Primary CompletionJun 2023
Study CompletionJun 2023
TodayJul 2026
First PostedJan 18, 2022
Enrollment StartJan 13, 2022
Primary CompletionJun 6, 2023
Study CompletionJun 21, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.5 years ago
Interventions
Tralokinumabdrug
Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration